A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy
Recruiting in Palo Alto (17 mi)
+17 other locations
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Pfizer
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this compound compared to placebo in patients with narcolepsy is hypothesized.
Research Team
PC
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
Inclusion Criteria
ISDC diagnosis of narcolepsy
Excessive Daytime Sleepiness in association with a diagnosis of narcolepsy
An MWT (Maintenance of Wakefulness Test) average sleep latency of under 15 minutes at Baseline
Treatment Details
Interventions
- PF-03654746 (Histaminergic Agent)
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: PF-03654746Active Control1 Intervention
At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Pfizer Investigational SiteLos Angeles, CA
Pfizer Investigational SiteOrange, CA
Pfizer Investigational SiteMacon, GA
Pfizer Investigational SiteLouisville, KY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Trials
4712
Patients Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13